Precision diagnosis and treatment of breast cancer in the post-CDK4/6 inhibitor era

doi:10.19401/j.cnki.1007-3639.2025.03.003

Abstract

Abstract:

Cyclin-dependent kinase (CDK)4/6 inhibitors plus endocrine therapy represents the standard first-line treatment for patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. The introduction of CDK4/6 inhibitors has significantly improved the prognosis of breast cancer patients. However, it has also brought new clinical challenges, such as disease progression and treatment resistance in many patients. Currently, there is a lack of standardized subsequent treatment options for patients whose disease progresses after CDK4/6 inhibitor combined with endocrine therapy. Endocrine therapy resistance can lead to tumor progression through estrogen receptor (ESR)-dependent or ESR-independent pathways. Novel endocrine agents have the potential to benefit breast cancer patients harboring ESR1 mutations. Patients with alterations in the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway may be particularly sensitive to targeted inhibitors of this pathway. Furthermore, newly approved or investigational antibody-drug conjugate (ADC), immunotherapy-based combinations, and novel cell cycle inhibitors have demonstrated promising anti-tumor activities. Precision medicine-based combination strategies not only expand clinical treatment options but also enable physicians to make personalized treatment decisions for patients. Biomarker-driven precision therapeutic strategies have emerged as a critical area of treatment development in the post-CDK4/6 inhibitor era.

Key words: Hormone receptor-positive advanced breast cancer, Cyclin-dependent kinase 4 and 6 inhibitor, Precision medicine, Endocrine therapy, Targeted therapy, Antibody-drug conjugate

CLC Number:

R737.9

LI Bin, TAO Zhonghua, HU Xichun. Precision diagnosis and treatment of breast cancer in the post-CDK4/6 inhibitor era[J]. China Oncology, 2025, 35(3): 273-282.

Figures/Tables 1

References 77

[1]	PEROU C M, SØRLIE T, EISEN M B, et al. Molecular portraits of human breast tumours[J]. Nature, 2000, 406(6797): 747-752.
[2]	FINN R S, ALESHIN A, SLAMON D J. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers[J]. Breast Cancer Res, 2016, 18(1): 17.
[3]	Ribociclib as first-line therapy for HR-positive, advanced breast cancer[J]. N Engl J Med, 2018, 379(26): 2582.
[4]	FINN R S, MARTIN M, RUGO H S, et al. Palbociclib and letrozole in advanced breast cancer[J]. N Engl J Med, 2016, 375(20): 1925-1936.
[5]	GOETZ M P, TOI M, CAMPONE M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer[J]. J Clin Oncol, 2017, 35(32): 3638-3646.
[6]	O’LEARY B, CUTTS R J, LIU Y, et al. The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial[J]. Cancer Discov, 2018, 8(11): 1390-1403. doi: 10.1158/2159-8290.CD-18-0264 pmid: 30206110
[7]	WANDER S A, COHEN O, GONG X Q, et al. The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor-positive metastatic breast cancer[J]. Cancer Discov, 2020, 10(8): 1174-1193. doi: 10.1158/2159-8290.CD-19-1390 pmid: 32404308
[8]	O’LEARY B, CUTTS R J, HUANG X, et al. Circulating tumor DNA markers for early progression on fulvestrant with or without palbociclib in ER⁺ advanced breast cancer[J]. J Natl Cancer Inst, 2021, 113(3): 309-317.
[9]	MILLIS S Z, IKEDA S, REDDY S, et al. Landscape of phosphatidylinositol-3-kinase pathway alterations across 19 784 diverse solid tumors[J]. JAMA Oncol, 2016, 2(12): 1565-1573.
[10]	SMYTH L M, ZHOU Q, NGUYEN B, et al. Characteristics and outcome of AKT1^E17K-mutant breast cancer defined through AACR project GENIE, a clinicogenomic registry[J]. Cancer Discov, 2020, 10(4): 526-535.
[11]	RINALDI J, SOKOL E S, HARTMAIER R J, et al. The genomic landscape of metastatic breast cancer: insights from 11 000 tumors[J]. PLoS One, 2020, 15(5): e0231999.
[12]	STURGILL E G, MISCH A, LACHS R, et al. Next-generation sequencing of patients with breast cancer in community oncology clinics[J]. JCO Precis Oncol, 2021, 5: 1297-1311. doi: 10.1200/PO.20.00469 pmid: 34994634
[13]	SOBHANI N, ROVIELLO G, CORONA S P, et al. The prognostic value of PI3K mutational status in breast cancer: a meta-analysis[J]. J Cell Biochem, 2018, 119(6): 4287-4292.
[14]	RUDOLPH M, ANZENEDER T, SCHULZ A, et al. AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection[J]. BMC Cancer, 2016, 16: 622.
[15]	MOSELE F, STEFANOVSKA B, LUSQUE A, et al. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer[J]. Ann Oncol, 2020, 31(3): 377-386.
[16]	MAYER E L, REN Y, WAGLE N, et al. PACE: A randomized phase Ⅱ study of fulvestrant, palbociclib, and avelumab after progression on cyclin-dependent kinase 4/6 inhibitor and aromatase inhibitor for hormone receptor-positive/human epidermal growth factor receptor-negative metastatic breast cancer[J]. J Clin Oncol, 2024, 42(17): 2050-2060.
[17]	LLOMBART-CUSSAC A, HARPER-WYNNE C, PERELLO A, et al. Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR⁺)/human epidermal growth factor receptor 2-negative (HER2^-) advanced breast cancer (ABC): PALMIRA trial[J]. J Clin Oncol, 2023, 41(16_suppl): 1001.
[18]	KALINSKY K, ACCORDINO M K, CHIUZAN C, et al. Randomized phase Ⅱ trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4/6 inhibition in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: MAINTAIN trial[J]. J Clin Oncol, 2023, 41(24): 4004-4013.
[19]	KALINSKY K, BIANCHINI G, HAMILTON E P, et al. Abemaciclib plus fulvestrant vs fulvestrant alone for HR⁺, HER2^- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: primary outcome of the phase 3 postMONARCH trial[J]. J Clin Oncol, 2024, 42(17_suppl): LBA1001.
[20]	JIANG Z F, LI W, HU X C, et al. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2019, 20(6): 806-815. doi: S1470-2045(19)30164-0 pmid: 31036468
[21]	ZHOU J M, WU X X, ZHANG H Q, et al. Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer[J]. Breast, 2022, 66: 255-261. doi: 10.1016/j.breast.2022.10.018 pmid: 36375386
[22]	SUO J J, ZHU K R, ZHUANG C Y, et al. Efficacy and safety of tucidinostat in patients with advanced hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: real-world insights[J]. Ann Transl Med, 2023, 11(12): 409. doi: 10.21037/atm-23-1913 pmid: 38213803
[23]	YUAN Y, ZHANG S H, WANG T, et al. Efficacy and safety of abemaciclib-based therapy versus tucidinostat-based therapy after progression on palbociclib in patients with HR⁺HER2^- metastatic breast cancer[J]. Transl Breast Cancer Res, 2023, 4: 10.
[24]	ZHENG Q, ZHOU H, WU H L, et al. 368P Tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR⁺/HER2^- advanced breast cancer after CDK4/6 inhibitors: Preliminary findings of a multi-center, phase Ⅱ study[J]. Ann Oncol, 2024, 35: S372.
[25]	BASELGA J, CAMPONE M, PICCART M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer[J]. N Engl J Med, 2012, 366(6): 520-529.
[26]	MO H J, RENNA C E, MOORE H C F, et al. Real-world outcomes of everolimus and exemestane for the treatment of metastatic hormone receptor-positive breast cancer in patients previously treated with CDK4/6 inhibitors[J]. Clin Breast Cancer, 2022, 22(2): 143-148.
[27]	ANDRÉ F, CIRUELOS E M, JURIC D, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1[J]. Ann Oncol, 2021, 32(2): 208-217.
[28]	RUGO H S, LEREBOURS F, CIRUELOS E, et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study[J]. Lancet Oncol, 2024, 25(12): e629-e638.
[29]	HANAN E J, BRAUN M G, HEALD R A, et al. Discovery of GDC-0077 (inavolisib), a highly selective inhibitor and degrader of mutant PI3Kα[J]. J Med Chem, 2022, 65(24): 16589-16621.
[30]	JHAVERI K, IM S A, SAURA C, et al. Abstract GS03-13: inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: phase Ⅲ INAVO120 primary analysis[J]. Cancer Res, 2024, 84 (9_Supplement): GS03-13.
[31]	MANNING B D, CANTLEY L C. AKT/PKB signaling: navigating downstream[J]. Cell, 2007, 129(7): 1261-1274. doi: 10.1016/j.cell.2007.06.009 pmid: 17604717
[32]	RIBAS R, PANCHOLI S, GUEST S K, et al. AKT antagonist AZD5363 influences estrogen receptor function in endocrine-resistant breast cancer and synergizes with fulvestrant (ICI182780) in vivo[J]. Mol Cancer Ther, 2015, 14(9): 2035-2048.
[33]	VITALE S R, MARTORANA F, STELLA S, et al. PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance[J]. Crit Rev Oncol Hematol, 2021, 162: 103334.
[34]	HOWELL S J, CASBARD A, CARUCCI M, et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial[J]. Lancet Oncol, 2022, 23(7): 851-864. doi: 10.1016/S1470-2045(22)00284-4 pmid: 35671774
[35]	TURNER N C, OLIVEIRA M, HOWELL S J, et al. Capivasertib in hormone receptor-positive advanced breast cancer[J]. N Engl J Med, 2023, 388(22): 2058-2070.
[36]	LEE H, CHO Y A, KIM D G, et al. Next-generation sequencing in breast cancer patients: real-world data for precision medicine[J]. Cancer Res Treat, 2024, 56(1): 149-161.
[37]	GRADISHAR W J, MORAN M S, ABRAHAM J, et al. Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2024, 22(5): 331-357.
[38]	HENRY N L, SOMERFIELD M R, DAYAO Z, et al. Biomarkers for systemic therapy in metastatic breast cancer: ASCO guideline update[J]. J Clin Oncol, 2022, 40(27): 3205-3221.
[39]	GENNARI A, ANDRÉ F, BARRIOS C H, et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer[J]. Ann Oncol, 2021, 32(12): 1475-1495. doi: 10.1016/j.annonc.2021.09.019 pmid: 34678411
[40]	SCHWARTZBERG L, KIM E S, LIU D, et al. Precision oncology: who, how, what, when, and when not?[J]. Am Soc Clin Oncol Educ Book, 2017, 37: 160-169. doi: 10.14694/EDBK_174176 pmid: 28561651
[41]	ROSIN J, SVEGRUP E, VALACHIS A, et al. Discordance of PIK3CA mutational status between primary and metastatic breast cancer: a systematic review and meta-analysis[J]. Breast Cancer Res Treat, 2023, 201(2): 161-169.
[42]	PICCART M, HORTOBAGYI G N, CAMPONE M, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2[J]. Ann Oncol, 2014, 25(12): 2357-2362.
[43]	JESELSOHN R, BUCHWALTER G, DE ANGELIS C, et al. ESR1 mutations: a mechanism for acquired endocrine resistance in breast cancer[J]. Nat Rev Clin Oncol, 2015, 12(10): 573-583.
[44]	BRETT J O, SPRING L M, BARDIA A, et al. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer[J]. Breast Cancer Res, 2021, 23(1): 85.
[45]	BIDARD F C, HARDY-BESSARD A C, DALENC F, et al. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial[J]. Lancet Oncol, 2022, 23(11): 1367-1377.
[46]	NEUPANE N, BAWEK S, GURUSINGHE S, et al. Oral SERD, a novel endocrine therapy for estrogen receptor-positive breast cancer[J]. Cancers (Basel), 2024, 16(3): 619.
[47]	BARDIA A, BIDARD F C, NEVEN P, et al. Abstract GS3-01: GS3-01 EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER⁺/HER2^- metastatic breast cancer: updated results by duration of prior CDK4/6i in metastatic setting[J]. Cancer Res, 2023, 83(5_Supplement): GS3-1.
[48]	JHAVERI K L, NEVEN P, CASALNUOVO M L, et al. Imlunestrant with or without abemaciclib in advanced breast cancer[J]. N Engl J Med, 2024.
[49]	SCOTT J S, MOSS T A, BALAZS A, et al. Discovery of AZD9833, a potent and orally bioavailable selective estrogen receptor degrader and antagonist[J]. J Med Chem, 2020, 63(23): 14530-14559.
[50]	OLIVEIRA M, POMINCHUCK D, NOWECKI Z, et al. Abstract GS3-02: GS3-02 camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: results of the randomized, multi-dose phase 2 SERENA-2 trial[J]. Cancer Res, 2023, 83( 5_Supplement): GS3-2-GS3-02.
[51]	MODI S N, JACOT W, YAMASHITA T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer[J]. N Engl J Med, 2022, 387(1): 9-20.
[52]	CURIGLIANO G, HU X C, DENT R A, et al. Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): primary results from DESTINY-Breast06 (DB-06)[J]. J Clin Oncol, 2024, 42(17_suppl): LBA1000.
[53]	YAN M, LV H M, NIU L M, et al. Efficacy and safety of HER2-ADC SHR-A1811 in HER2-positive breast cancer with brain metastases[J]. J Clin Oncol, 2024, 42(16_suppl): e13006.
[54]	ZHANG J, LIU R J, GAO S P, et al. Phase I study of A166, an antibody-drug conjugate in advanced HER2-expressing solid tumours[J]. NPJ Breast Cancer, 2023, 9(1): 28.
[55]	WANG J Y, LIU Y J, ZHANG Q Y, et al. RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: a pooled analysis of two studies[J]. J Clin Oncol, 2021, 39(15_suppl): 1022.
[56]	JIANG Z F, SUN T, WANG X J, et al. A multiple center, open-label, single-arm, phase Ⅱ clinical trial of MRG002, an HER2-targeted antibody-drug conjugate, in patients with HER2-low expressing advanced or metastatic breast cancer[J]. J Clin Oncol, 2022, 40(16_suppl): 1102.
[57]	VIDULA N, YAU C, RUGO H. Trophoblast cell surface antigen 2 gene (TACSTD2) expression in primary breast cancer[J]. Breast Cancer Res Treat, 2022, 194(3): 569-575.
[58]	RUGO H S, BARDIA A, MARMÉ F, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial[J]. Lancet, 2023, 402(10411): 1423-1433. doi: 10.1016/S0140-6736(23)01245-X pmid: 37633306
[59]	MERIC-BERNSTAM F, KROP I, JURIC D, et al. Abstract PD13-08: PD13-08 phase 1 TROPION-PanTumor01 study evaluating datopotamab deruxtecan (dato-DXd) in unresectable or metastatic hormone receptor-positive/HER2-negative breast cancer (BC)[J]. Cancer Res, 2023, 83( 5_Supplement): PD13-8-PD13-08.
[60]	BARDIA A, JHAVERI K, IM S A, et al. LBA11 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR⁺/HER2^-) breast cancer (BC): primary results from the randomised phase Ⅲ TROPION-Breast01 trial[J]. Ann Oncol, 2023, 34: S1264-S1265.
[61]	WANG S, ZHANG Q, JIANG Z, et al. 38MO Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in patients (pts) with pre-treated inoperable/metastatic hormone receptor-positive, HER2-negative (HR⁺/HER2^-) breast cancer (BC): results from TROPION-Breast01 China cohort[J]. Ann Oncol, 2024, 35: S1418-S1419.
[62]	OUYANG Q, YIN Y, SONG L, et al. 380MO SKB264 (MK-2870) in previously treated hormone receptor-positive (HR⁺)/HER2-negative metastatic breast cancer (mBC): results from a phase Ⅰ/Ⅱ, single-arm, basket trial[J]. Ann Oncol, 2023, 34: S337.
[63]	ZHAO J, HUANG F B, XU X, et al. Case report: Prolonged benefit of ESG401, a Trop2 antibody-drug conjugate, in endocrine-refractory hormone receptor-positive, HER-2 negative metastatic breast cancer[J]. Front Oncol, 2024, 14: 1444431.
[64]	TONG Y J, FAN X B, LIU H, et al. Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: mechanisms, clinical applications, and future directions[J]. Front Immunol, 2024, 15: 1495675.
[65]	PISTILLI B, PIEROTTI L, LACROIX-TRIKI M, et al. 340O Efficacy, safety and biomarker analysis of ICARUS-BREAST01: a phase Ⅱ study of patritumab deruxtecan (HER3-DXd) in patients (pts) with HR⁺/HER2^- advanced breast cancer (ABC)[J]. Ann Oncol, 2024, 35: S357.
[66]	MEDFORD A J, NIEMIERKO A, ABELMAN R O, et al. Nectin-4 expression in primary breast cancer and associated clinical outcomes[J]. J Clin Oncol, 2024, 42(16_suppl): 570.
[67]	CAO A T, HIGGINS S, STEVENS N, et al. Abstract 2742: additional mechanisms of action of ladiratuzumab vedotin contribute to increased immune cell activation within the tumor[J]. Cancer Res, 2018, 78(13_Supplement): 2742.
[68]	CARDOSO F, JIA L, HIRSHFIELD K, et al. KEYNOTE-756: Randomized, double-blind, phase Ⅲ study of pembrolizumab vs placebo+neoadjuvant chemotherapy (CT) and adjuvant endocrine therapy (ET) for high-risk, early-stage estrogen receptor-positive human epidermal growth factor receptor 2-negative (ER⁺/HER2^-) breast cancer (BC)[J]. Ann Oncol, 2019, 30: iii38.
[69]	LOI S, MCARTHUR H L, HARBECK N, et al. A phase Ⅲ trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER⁺/HER2^- primary breast cancer: CheckMate 7FL[J]. J Clin Oncol, 2020, 38(15_suppl): TPS604.
[70]	IWAI T, SUGIMOTO M, WAKITA D, et al. Topoisomerase Ⅰ inhibitor, irinotecan, depletes regulatory T cells and up-regulates MHC class Ⅰ and PD-L1 expression, resulting in a supra-additive antitumor effect when combined with anti-PD-L1 antibodies[J]. Oncotarget, 2018, 9(59): 31411-31421.
[71]	GARRIDO-CASTRO A C, KIM S E, DESROSIERS J, et al. SACI-IO HR⁺: a randomized phase Ⅱ trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer[C]. Chicago: ASCO, 2024.
[72]	SCHOTT A F, HURVITZ S, MA C, et al. Abstract GS3-03: GS3-03 ARV-471, a PROTAC^® estrogen receptor (ER) degrader in advanced ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer: phase 2 expansion (VERITAC) of a phase 1/2 study[J]. Cancer Res, 2023, 83(5_Supplement): GS3-3-GS3-03.
[73]	HAMILTON E, JESELSOHN R, HURVITZ S, et al. Abstract PS15-03: vepdegestrant, a PROteolysis TArgeting chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib in ER-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: phase 1b cohort[J]. Cancer Res, 2024, 84( 9_Supplement): PS15-3-PS15-03.
[74]	HAMILTON E P, WANG J S, PLUARD T J, et al. Phase Ⅰ/Ⅱ study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER⁺), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer[J]. J Clin Oncol, 2021, 39(15_suppl ) : 1018.
[75]	PARISIAN A D, BARRATT S A, HODGES-GALLAGHER L, et al. Palazestrant (OP-1250), a complete estrogen receptor antagonist, inhibits wild-type and mutant ER-positive breast cancer models as monotherapy and in combination[J]. Mol Cancer Ther, 2024, 23(3): 285-300.
[76]	MUKOHARA T, PARK Y H, SOMMERHALDER D, et al. A phase 1 dose expansion study of a first-in-class KAT6 inhibitor (PF-07248144) in patients with advanced or metastatic ER⁺ HER2-breast cancer[J]. J Clin Oncol, 2024, 42(16_suppl): 3006.
[77]	YAP T A, GIORDANO A, HAMILTON E P, et al. First-in-human first-in-class phase 1/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+ HER2- mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy[J]. J Clin Oncol, 2023, 41(16_suppl ) : 3009.

Drug	Trial name	Trial design	Prior CDK4/6 inhibitor	Median PFS	Reference
Continuing CDK4/6 inhibitor	postMONARCH	Phase Ⅲ, n=368, abemaciclib+fulvestrant vs placebo+fulvestrant	100.0%	6.0 months vs 5.3 months, HR=0.73, P=0.02	[19]
mTORi everolimus	BOLERO-2	Phase Ⅲ, n=724, everolimus+exemestane vs placebo+exemestane	0.0%	7.8 months vs 3.2 months, HR=0.45, P<0.000 1	[42]
HDACi chidamide	ACE	Phase Ⅲ, n=356, chidamide+exemestane vs placebo+exemestane	0.0%	7.4 months vs 3.8 months, HR=0.75, P=0.033	[20]
	NCT05411380	Phase Ⅱ, n=43, chidamide+metronomic capecitabine and endocrine therapy	100.0%	5.55 months	[24]
PI3Ki alpelisib	SOLAR-1	Phase Ⅲ, n=572 (PIK3CA mutant n=341), fulvestrant+alpelisib vs placebo+fulvestrant	5.9%	PIK3CA mutant: 11.0 months vs 5.7 months, HR=0.65, P<0.001	[27]
PI3Ki inavolisib	INAVO120	Phase Ⅲ, n=325, fulvestrant+palbociclib+inavolisib vs fulvestrant+palbociclib+placebo	1.2%	15.0 months vs 7.3 months, HR=0.43, P<0.000 1	[30]
AKTi capivasertib	CAPItello-291	Phase Ⅲ, n=708 (AKT pathway-altered: 41%), fulvestrant+capivasertib vs fulvestrant +placebo	69.0%	ITT: 7.2 months vs 3.6 months, HR=0.6, P<0.001; AKT pathway-altered: 7.3 months vs 3.1 months, HR=0.5, P<0.001	[35]